CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsLow earnings quality
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.34BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.21xvs all stocks
52-Week Change
242.11%vs all stocks
Market Capitalization
1.34BUSDvs all stocks (USD)
Enterprise Value
1.28BUSDvs all stocks (USD)
Forward P/E
-27.10xvs Biotechnology peers
Price to Book (MRQ)
30.37xvs Biotechnology peers
Enterprise to EBITDA
-26.22xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-25.71%vs Biotechnology peers
Return on Equity (TTM)
-141.68%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Sep 27, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-48.76MUSDvs all stocks (USD)
Net Income (TTM)
-92.57MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-12.81MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-20.26MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-42.29MUSDvs all stocks (USD)
Pre-tax Income
-42.51MUSDFY2025 · Dec 31, 2025Income Tax Expense
121.00KUSDFY2025 · Dec 31, 2025Net Income
-42.63MUSDFY2025 · Dec 31, 2025EBIT
-42.16MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-37.29MUSDFY2025 · Dec 31, 2025Research & Development
32.06MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
10.22MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
3.84MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
347.00KUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-42.63MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-29.80MUSDFY2025 · Dec 31, 2025Free Cash Flow
-35.87MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
12.20MUSDFY2025 · Dec 31, 2025Income Tax Paid
4.00KUSDFY2025 · Dec 31, 2025Interest Paid
381.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-42.63MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.23MUSDFY2025 · Dec 31, 2025Stock-based Compensation
10.62MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-245.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
337.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
891.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-6.08MUSDFY2025 · Dec 31, 2025Purchase of Investments
-70.49MUSDFY2025 · Dec 31, 2025Sale of Investments
55.98MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-20.59MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
-5.15MUSDFY2025 · Dec 31, 2025Net Short-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Net Financing Cash Flow
40.34MUSDFY2025 · Dec 31, 2025Shares Outstanding
90.18MSharesUpdated Sep 27, 2026Float Shares
64.10MSharesUpdated Sep 27, 2026Shares Short
3.48MSharesUpdated Sep 27, 2026Short Ratio
5.72daysvs all stocks
Short % of Shares Outstanding
5.42%vs all stocks
% Held by Insiders
30.50%vs all stocks
% Held by Institutions
9.15%vs all stocks
Total Cash (MRQ)
100.64MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.09USDUpdated Sep 27, 2026Total Debt (MRQ)
15.15MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.3439xvs Biotechnology peers
Current Ratio (MRQ)
11.09xvs Biotechnology peers
Book Value per Share (MRQ)
0.4770USDUpdated Sep 27, 2026Total Assets
105.65MUSDvs all stocks (USD)
Total Current Assets
78.30MUSDFY2025 · Dec 31, 2025Total Liabilities
28.55MUSDFY2025 · Dec 31, 2025Total Non-current Assets
27.35MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
18.05MUSDFY2025 · Dec 31, 2025Total Current Liabilities
10.51MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
12.20MUSDFY2025 · Dec 31, 2025Other Short-term Investments
60.92MUSDFY2025 · Dec 31, 2025Accounts Payable
3.87MUSDFY2025 · Dec 31, 2025Short-term Debt
1.13MUSDFY2025 · Dec 31, 2025Long-term Debt
12.60MUSDFY2025 · Dec 31, 2025Common Stock (Book)
0.00USDFY2025 · Dec 31, 2025Retained Earnings
-190.14MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
77.10MUSDvs all stocks (USD)
52-Week Low
3.43USDUpdated Sep 27, 202652-Week High
15.79USDUpdated Sep 27, 202652-Week Change
242.11%vs all stocks
Beta
1.21xvs all stocks
50-Day MA
13.91USDUpdated Sep 27, 2026200-Day MA
9.50USDUpdated Sep 27, 2026Avg 10-Day Volume
492.76KSharesUpdated Sep 27, 2026Avg 30-Day Volume
574.11KSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-1.04USDUpdated Sep 27, 2026Other Income / Expense
-3.64MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.52
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 33,357,653.812
Market cap is $1.34B, above the global median of $1.18BNotable
Market cap (USD): 1,344,632,359Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Sinonep-Allsino Bio Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
EL.En. S.p.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Chengdu Easton Bio Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Hotgen Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Garden Bio-chemical High-tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
GenFleet Therapeutics (Shanghai) Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Vcanbio Cell & Gene Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Conmed Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Oric Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule